Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2001 | Fast Track | Series C | 0 |
11/2006 | Intradigm Corporation | Series A | 16M |
9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
7/2004 | Trubion Pharmaceuticals | Series B | 32M |
11/2020 | Inipharm | Series A | 0 |
2/2015 | Merganser Biotech | Series A | 28M |
10/2015 | Gritstone Bio | Series A | 102M |
10/2014 | Imago BioSciences | Series A | 26.5M |
11/2020 | Imago BioSciences | Series C | 80M |
3/2019 | Imago BioSciences | Series B | 40M |
8/2003 | Zonare Medical Systems | Series D | 6.5M |
11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
3/2019 | Scout Bio | Series B | 20M |
5/2003 | Quantum Dot | Series B | 1.5M |
4/2010 | Achaogen | Series C | 56M |
9/2002 | Alexza Pharmaceuticals | Series A | 0 |
12/2007 | PowerVision | Series B | 20M |
10/2021 | Radionetics Oncology | Private Equity Round | 30M |
11/2021 | Tricida | Post-IPO Equity | 42M |
9/2018 | Arcutis Biotherapeutics | Series B | 58M |
1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
4/2020 | Aspen Neuroscience | Series A | 0 |
11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
6/2016 | Alpine Immune Sciences | Series A | 48M |
1/2014 | Ignyta | Debt Financing | 10M |
4/2014 | Sierra Oncology | Series D | 0 |
5/2007 | Pegasus Biologics | Series C | 20M |
1/2020 | Galera Therapeutics | Venture Round | - |
6/2010 | Zeltiq Aesthetics | Series D | 25M |
6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
3/2017 | Vaxcyte | Series B | 60M |
7/2008 | CVRx | Series E | 0 |
6/2008 | EBR Systems | Series C | 35M |
3/2020 | Vaxcyte | Series D | 0 |
8/2008 | Glaukos | Series D | 35M |
9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
8/2000 | PatientKeeper | Series B | 0 |
7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
1/2019 | Sojournix | Series C | 44M |
9/2019 | Passage Bio | Series B | 110M |
5/2007 | Marcadia Biotech | Series A | 15M |
1/2012 | Moximed | Venture Round | 1.8M |
8/2008 | Calibra Medical | Series B | 35M |
2/2007 | Chimerix | Series D | 23.1M |
4/2017 | Cirius Therapeutics | Series A | 0 |
8/2012 | Millendo Therapeutics | Series A | 16M |
6/2005 | Pegasus Biologics | Series B | 10M |
7/2020 | MBX Biosciences | Series A | 34.6M |
1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
5/2017 | Iterum Therapeutics | Series B | 65M |
11/2009 | Calypso Medical | Series E | 50M |
12/2003 | Avera Pharmaceutical | Series B | 8M |
11/2007 | AnaptysBio | Series B | 0 |
10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
5/2020 | Lengo Therapeutics | Series A | 15M |
3/2016 | Outpost Medicine | Series A | 41M |
6/2005 | Cierra | Funding Round | 21M |
8/2018 | Cirius Therapeutics | Series A | 9M |
10/2003 | Cotherix | Series C | 55M |
1/2007 | Calypso Medical | Series D | 42.2M |
1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
2/2015 | Laguna Pharmaceuticals | Series B | 30M |
10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
9/2020 | Silverback Therapeutics | Series C | 85M |
12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
7/2015 | AnaptysBio | Series D | 40M |
8/2009 | Barosense | Series D | 27M |
9/2005 | Amicus Therapeutics | Series C | 55M |
6/2016 | Iovance Biotherapeutics | Equity | 100M |
7/2013 | Alcresta | Series B | 10M |
7/2004 | Zonare Medical Systems | Series E | 34M |
1/2009 | Intradigm Corporation | Series B | 0 |
8/2021 | Sonoma BioTherapeutics | Series B | 0 |
3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
12/2003 | Portola Pharmaceuticals | Series A | 21M |
11/2005 | Portola Pharmaceuticals | Series B | 46M |
7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
6/2003 | Xoft | Series B | 0 |
5/2007 | Portola Pharmaceuticals | Series C | 70M |
4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
3/2020 | Amunix | Series A | 0 |
5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
4/2007 | Xoft | Series D | 0 |
5/2005 | Xoft | Series C | 0 |
3/2004 | Cardiac Dimensions | Series C | 15M |
3/2000 | MEDCHANNEL | Series B | 42M |
5/2004 | Amicus Therapeutics | Series B | 31M |
8/2008 | PatientKeeper | Series F | 0 |
9/2006 | Amicus Therapeutics | Series D | 60M |
2/2019 | Passage Bio | Series A | 115.5M |
2/2013 | Glaukos | Series F | 30M |
2/2011 | Glaukos | Series E | 0 |
2/2008 | Zonare Medical Systems | Equity | 30M |
8/2018 | Millendo Therapeutics | Venture Round | 30M |
1/2016 | Millendo Therapeutics | Series B | 0 |
6/2004 | PatientKeeper | Series D | 0 |
5/2009 | Clovis Oncology | Venture Round | 145M |
2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
1/2005 | Alexza Pharmaceuticals | Series D | 0 |
4/2008 | Stromedix | Series B | 25M |
3/2006 | PowerVision | Series A | 2M |
9/2017 | Gritstone Bio | Series B | 93M |
1/2007 | Calixa Therapeutics | Funding Round | - |
5/2021 | Hummingbird Bioscience | Series C | 0 |
10/2008 | Alnara Pharmaceuticals | Series A | 20M |
9/2021 | HilleVax | Equity | 135M |
2/2021 | Seraxis | Series C | 40M |
1/2023 | Curve Beam | Funding Round | 0 |
1/2020 | Bellus Health | Post-IPO Equity | - |
12/2003 | FlowCardia | Series B | 12M |
2/2007 | Pivot Medical | Series A | 2M |
3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
4/2002 | Avera Pharmaceutical | Series A | 20M |
6/2010 | Incline Therapeutics | Series A | 43M |
8/2007 | Tobira Therapeutics | Series A | 31M |
8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
3/2009 | Stemgent | Series B | 14M |
11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
1/2013 | Scilex Holding Company | Venture Round | - |
9/2002 | Glaukos | Series A | 10M |
1/2018 | ARMO BioSciences | Venture Round | - |
8/2015 | Calibrium | Convertible Note | 1.7M |
1/2022 | Metagenomi | Series B | 0 |
1/2014 | PowerVision | Series D | 0 |
4/2016 | Entasis Therapeutics | Series B | 50M |
1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
11/2021 | SanReno Therapeutics | Funding Round | 0 |
3/2021 | Amunix | Series B | 117M |
1/2006 | Primaeva Medical | Series A | 1.3M |
1/2008 | Ascension Orthopedics | Series D | 21M |
4/2008 | Nuon Therapeutics | Series B | 27M |
5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
2/2015 | Cidara Therapeutics | Series B | 42M |
11/2018 | Mirum Pharmaceuticals | Series A | 120M |
12/2007 | Cardiac Dimensions | Series D | 0 |
8/2007 | FlowCardia | Series C | 0 |
1/1996 | Corixa | Venture Round | - |
12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
12/2006 | Primaeva Medical | Series B | 7M |
12/2014 | Allena Pharmaceuticals | Series B | 0 |
6/2006 | PatientKeeper | Series E | 0 |
1/2020 | REGENXBIO | Post-IPO Equity | - |
11/2011 | Allena Pharmaceuticals | Series A | 15M |
1/2005 | PowerVision | Series A | 4.4M |
5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
4/2012 | Alcresta | Series A | 10M |
3/2016 | Iterum Therapeutics plc | Series A | 40M |
3/2007 | Stromedix | Series A | 1M |
12/2007 | Pivot Medical | Series B | 0 |
7/2002 | Barosense | Series A | 6.2M |
1/1993 | VIVUS | Venture Round | - |
6/2017 | Alteon Health | Private Equity Round | - |
12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
3/2020 | Molecular Templates | Post-IPO Debt | 45M |
1/1991 | CV Therapeutics | Funding Round | - |
3/2010 | Nuon Therapeutics | Venture Round | 6M |
8/2021 | Immunovant | Corporate Round | 200M |
12/2015 | Allena Pharmaceuticals | Series C | 0 |
11/2007 | Zonare Medical Systems | Series G | 30M |
5/2007 | Arete Therapeutics | Series A | 35M |
8/2010 | Nuon Therapeutics | Venture Round | 10M |
11/2006 | Bariatric Partners | Series B | 0 |
9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
12/2009 | EBR Systems | Venture Round | 15M |
6/2020 | Lassen Therapeutics | Series A | 31M |
1/2000 | ZymoGenetics | Funding Round | - |
8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
5/2016 | Aptinyx | Series A | 0 |
6/2005 | Pegasus Biologics | Series B | 10M |
10/2020 | Scholar Rock | Post-IPO Debt | 50M |
1/2006 | Xoft | Series C | 0 |
7/2010 | BARRX Medical | Series D | 15M |
9/2021 | Alpine Immune Sciences | Private Placement | 91M |
1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
8/2005 | Cerexa Inc. | Series A | 0 |
1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
4/2020 | Dascena | Series B | 50M |
2/2000 | PatientKeeper | Series A | 8.6M |
12/2004 | Barosense | Series B | 6.2M |
3/2016 | Zavante Therapeutics | Series A | 45M |
10/2005 | EBR Systems | Series B | 21M |
1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
3/2013 | AcertaPharma | Series A | 60M |
1/2020 | Epizyme | Post-IPO Equity | - |
1/1998 | Array BioPharma | Venture Round | - |
7/2006 | BARRX Medical | Series C | 27.8M |
2/2011 | Chimerix | Series F | 45M |
1/2000 | Simpata Inc | Series B | 20M |
6/2014 | Cidara Therapeutics | Series A | 32M |
6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
1/2017 | The CORE Institute | Private Equity Round | - |
2/2000 | Xenoport | Series A | 15.9M |
3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
3/2013 | Achaogen | Series D | 18.9M |
8/2004 | Avera Pharmaceutical | Series C | 0 |
10/2021 | Scout Bio | Series B | 0 |
7/2008 | Collegium Pharmaceutical | Series D | 0 |
1/1991 | Tularik | Funding Round | - |
9/2010 | Tobira Therapeutics | Series B | 31M |
10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
2/2019 | Recida Therapeutics | Series A | 8.5M |
1/2020 | IVERIC bio | Post-IPO Equity | - |
5/2007 | CVRx | Series D | 65M |
1/1996 | ViroPharma | Funding Round | - |
5/2007 | Pegasus Biologics | Series C | 20M |
7/2011 | PowerVision | Series C | 24M |
1/2005 | Calypso Medical | Series C | 6.8M |
5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
9/2000 | Zonare Medical Systems | Series B | 9.5M |
12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
12/2007 | Barosense | Series C | 11.2M |
10/2007 | Altiris Therapeutics | Series B | 0 |
11/2017 | Outpost Medicine, LLC | Series A | 20M |
11/2009 | Calibra Medical | Venture Round | 1.4M |
6/2004 | EBR Systems | Series A | 5.2M |
11/2017 | Mavupharma | Series A | 0 |
2/2009 | Primaeva Medical | Series C | 6M |
1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
12/2017 | Aptinyx | Series B | 70M |
1/2022 | Metagenomi | Series B | 0 |
12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
11/2021 | SanReno Therapeutics | Funding Round | 0 |
11/2021 | Tricida | Post-IPO Equity | 0 |
11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
10/2021 | Scout Bio | Series B | 0 |
10/2021 | Radionetics Oncology | Private Equity Round | 0 |
9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
9/2021 | HilleVax | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|